Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
AstraZeneca
Boehringer Ingelheim
McKinsey
Express Scripts

Last Updated: January 27, 2023

Details for Patent: 6,214,865


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 6,214,865 protect, and when does it expire?

Patent 6,214,865 protects HALAVEN and is included in one NDA.

Protection for HALAVEN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty patent family members in twenty-one countries.

Summary for Patent: 6,214,865
Title: Macrocyclic analogs and methods of their use and preparation
Abstract:The invention provides halichondrin analogs having pharmaceutical activity, such as anticancer or antimitotic (mitosis-blocking) activity, and methods of identifying agents that induce a sustained mitotic block in a cell after transient exposure of the cell to the agents.
Inventor(s): Littlefield; Bruce A. (Andover, MA), Palme; Monica H. (San Jose, CA), Seletsky; Boris M. (Andover, MA), Towle; Murray J. (Auburn, NH), Yu; Melvin J. (Andover, MA), Zheng; Wanjun (Londonberry, NH)
Assignee: Eisai Co., Ltd. (Tokyo, JP)
Application Number:09/334,488
Patent Claim Types:
see list of patent claims
Compound; Use;

Drugs Protected by US Patent 6,214,865

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,214,865

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 502932 See Plans and Pricing
Australia 2003284242 See Plans and Pricing
Australia 4573999 See Plans and Pricing
Australia 762998 See Plans and Pricing
Brazil 9911326 See Plans and Pricing
Canada 2335300 See Plans and Pricing
Canada 2632433 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Medtronic
Harvard Business School
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.